VF
STSA

Virtu Financial’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Virtu Financial’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,096
Closed -$61K – 2407
2022
Q3 		$61K Buy
+10,096
New +$57.3K 0.01% 1166
2021
Q1 		– Sell
-10,133
Closed -$47K – 2200
2020
Q4 		$47K Sell
10,133
-28,929
-74% -$125K 0.01% 1243
2020
Q3 		$152K Buy
+39,062
New +$785K 0.03% 649

Other funds holding STSA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Virtu Financial's STSA Position: Q4 2022 in Review

Virtu Financial sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 10,096 shares — an estimated $61K sold.

Virtu Financial first reported a position in STSA in Q3 2020 and held it in 3 quarters. The position peaked at $152K in Q3 2020. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

  • Virtu Financial reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Virtu Financial sold 10,096 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $61K.
  • Virtu Financial first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Virtu Financial's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $152K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.